Curasight A/S (NGM:CURAS)

Sweden flag Sweden · Delayed Price · Currency is SEK · Price in DKK
4.660
-0.400 (-7.91%)
At close: Apr 16, 2025
-53.40%
Market Cap 146.55M
Revenue (ttm) n/a
Net Income (ttm) -58.71M
Shares Out 21.15M
EPS (ttm) -2.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,714
Average Volume 7,563
Open 5.340
Previous Close 5.060
Day's Range 4.660 - 5.340
52-Week Range n/a
Beta 0.17
RSI 26.09
Earnings Date Mar 26, 2025

About Curasight

Curasight A/S, a biotech company, develops treatment of cancer. The company exploits a novel Positron Emissions Tomography (PET) imaging platform that targets the urokinase-type plasminogen activator receptor (uPAR). It develops uTRACE for enhanced evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trials; and uTREAT, a uPAR targeted radionuclide therapy is using uTRACE together with radiation therapy to irradiate cancer with limited irradiation of healthy tissue. The company focuses on gen... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2013
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol CURAS
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

There is no news available yet.